Category: Oncology

VISION Trial: Lutetium-177–PSMA-617 for Metastatic Prostate Cancer

The VISION trial was a phase 3 international, open-label study that aimed to evaluate the efficacy of Lutetium-177 (177Lu)–PSMA-617, a radioligand therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). This type of cancer remains fatal despite recent advancements, and prostate-specific membrane antigen (PSMA) is highly expressed in mCRPC. The trial enrolled patients who had […]

KEYNOTE 671 Trial: Perioperative Pembrolizumab in Early-Stage NSCLC

KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant and adjuvant pembrolizumab in combination with chemotherapy compared to chemotherapy alone. Methods:The trial enrolled participants […]

ZUMA 7 Trial: Axi-Cel Therapy- A New Hope for Patients with Early Relapsed or Refractory Large B-Cell Lymphoma

ZUMA 7 Trial Summary Patients with early relapsed or refractory large B-cell lymphoma often face poor prognoses after receiving first-line chemoimmunotherapy. However, a recent international, phase 3 trial has demonstrated promising results with the use of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy. In this trial, patients with large B-cell lymphoma, […]

SUNLIGHT Trial: Prolonging Survival for Advanced Colorectal Cancer Patients with Trifluridine–Tipiracil and Bevacizumab

The groundbreaking “SUNLIGHTTrial” recently highlighted the potential of the combined treatment of Trifluridine–Tipiracil (FTD–TPI) and Bevacizumab in extending the lifespan of patients with advanced colorectal cancer. The promising phase 3 study builds on prior research suggesting the efficacy of FTD–TPI in these cases, and points to the enhanced potential of FTD–TPI when used in combination […]

CATCH Trial Summary: Tinzaparin for VTE in Cancer

2015 CATCH TRIAL Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer phase 3, multinational, open-label, randomized controlled trial Objective: To assess the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic venous thromboembolism (VTE) in patients with active cancer 900 Patients Inclusion criteria: Patients ≥ 18 […]

ALLIANCE Trial Summary: Axillary Dissection in Breast Cancer

2020 ALLIANCE TRIAL Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis Multicenter, phase 3, randomized controlled trial M Objective: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node […]

ALEX Trial Summary: Alectinib vs. Crizotinib in NSCLC

2017 ALEX TRIAL Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer international, open-label, randomised phase 3 trial Σ Objective: To compare alectinib (600 mg twice daily) with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. 303 patients Participants > 18 years of age, ALK-positive advanced NSCLC, ECOG […]

AGE Trial Summary: Mammogram Screening for Breast Cancer

AGE: Effect of mammographic screening from age 40 years on breast cancer mortality Multicenter, open label randomized comparative trial Objective: To assess if initiation of breast cancer screening with mammograms at age 40-41 reduces breast cancer mortality Women age 39-41 receiving care by a primary care 160,840 doctor associated with a study center were randomized […]

IPASS Trial Summary: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma

2009 IPASS TRIAL Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma phase 3, multicenter, open-label, parallel-group, randomised controlled trial d a Objective: To assess the effect of gefitinib as compared with carboplatin-paclitaxel for adenocarcinoma of the lung in nonsmokers or former light smokers in East Asia & the role of an EGFR mutation as a predictor of […]

TRICOP Trial Summary: Transfusion strategy in critically ill Oncologic patients

2017 2017 TRICOP TRIAL Liberal vs restrictive transfusion strategy in critically ill oncologic patients: The transfusion requirements in critically ill oncologic Single-center, randomized, double-blind controlled trial Objective: To assess whether a restrictive strategy of RBC transfusion reduces 28-day mortality when compared with a liberal strategy in cancer patients with septic shock. E 157 Inclusion criteria: […]